Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XBiotech Inc.XBIT · Entity 7044 | Director · 10% owner | June 20, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XBiotech Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2034-06-20 | Direct | 37,500 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 37,500 · Balance 37,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2018 Filed Jun 21, 2018 15:14 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-18-038902 · doc4.xml · derivative · entry 1 MCKENZIE W THORPE · CIK 0001211462 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-19 Read SEC document |
| June 19, 2017 Filed Jun 23, 2017 14:55 UTC Amendment | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 50,000 | $4.24 Strike: $4.24 | $212,000.00 |
DisclosureSEC source: 0001209191-17-041620 · doc4a.xml · derivative · entry 1 MCKENZIE W THORPE · CIK 0001211462 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2017 Filed Jun 23, 2017 14:18 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 50,000 | $4.24 Strike: $4.24 | $212,000.00 |
DisclosureSEC source: 0001209191-17-041610 · doc4.xml · derivative · entry 1 MCKENZIE W THORPE · CIK 0001211462 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On September 14, 2016 (the Grant Date) Fabrizio Bonanni was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purcahse shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market, with an expiry of ten years from the Grant Date. Half of the Options vest on December 20, 2016 and another half of the Options vest on June 20, 2017. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 15:07 UTC | XBiotech Inc. XBIT · Entity 7044 | Exercise / conversionStock Option · Derivative | 50,000 | $13.26 Strike: $13.26 | $663,000.00 |
DisclosureSEC source: 0001209191-16-141754 · doc4.xml · derivative · entry 1 MCKENZIE W THORPE · CIK 0001211462 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On September 14, 2016 (the Grant Date) W. Thorpe McKenzie was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purcahse shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market, with an expiry of ten years from the Grant Date. Half of the Options vest on December 20, 2016 and another half of the Options vest on June 20, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.